Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Erectile dysfunction drug tested for bladder control in women

NCT ID NCT07416968

Symptom relief Sponsor: Mansoura University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two medicines—tadalafil (a drug often used for erectile dysfunction) and solifenacin (a standard OAB treatment)—to see which works better for women with overactive bladder. About 480 women in Egypt will take one pill daily for 12 weeks. Researchers will track symptoms like urgency and frequency using bladder diaries and questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tadalafil 5 mg and solifenacin 5 mg
What this could lead to
If tadalafil works better, it could offer women a new, once-daily pill option for overactive bladder with possibly fewer side effects.
What could go wrong
This is a phase 4 trial comparing two existing drugs, so no breakthrough is expected. Tadalafil may not outperform solifenacin, and side effects like headache or upset stomach are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 480 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * OAB symptoms persisting for ≥3 months * OAB Symptom Score (OABSS) \> 5 and urgency sub-score of OABSS ≥ 2 * Ability and willingness to provide informed consent. Exclusion Criteria: * Active urinary tract infection. * Stress urinary incontinence (SUI) as primary diagnosis, or mixed urinary incontinence with predominant SUI * Pelvic organ prolapse stage ≥II according to POP-Q system. * History of pelvic radiation. * History of neurosurgical interventions. * Pregnancy or breastfeeding. * Neuropathic diseases affecting the lower urinary tract. * History of genitourinary malignancy. * Post-void residual urine (PVR) \> 150 ml. * Vesical or lower ureteric stones. * Uncontrolled diabetes mellitus (HbA1c \> 7). * Any psychological or psychiatric disorders. * Contraindications or allergy to the used medications. * History of surgeries in the urinary bladder. * History of pelvic surgeries within 6 months. * Voiding dysfunctions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overactive bladder (OAB) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

overactive bladder Urinary Incontinence, Urge

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overactive bladder (OAB) Overactive bladder syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    14 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cairo University, faculty of medicine

    RECRUITING

    Cairo, 1211, Egypt

  • Faculty of Medicine - Assiut University

    RECRUITING

    Asyut, Egypt

  • Faculty of Medicine - Banī Suwayf University

    RECRUITING

    Banī Suwayf, Egypt

  • Faculty of Medicine, South Valley University

    RECRUITING

    Qina, Egypt

  • Faculty of medicine, Ain Shams University

    RECRUITING

    Cairo, 1181, Egypt

  • Faculty of medicine, Alexandria University

    RECRUITING

    Alexandria, Egypt

  • Faculty of medicine, Aswan university

    RECRUITING

    Aswān, Egypt

  • Faculty of medicine, Menofia Univeristy

    RECRUITING

    Shibīn al Kawm, Al-Minūfiyyah, Egypt

  • Faculty of medicine, Sohag Univeristy

    RECRUITING

    Sohag, Egypt

  • Faculty of medicine, Tanta University

    RECRUITING

    Tanta, Gharbia Governorate, Egypt

  • Faculty of medicine, Zagazig University

    RECRUITING

    Zagazig, Al-Sharqia, Egypt

  • Faculty of medicine, minia university

    RECRUITING

    Al Minyā, Egypt

  • Urology and Nephrology Center, Mansoura University

    RECRUITING

    Al Mansurah, Dakahlia Governorate, 35516, Egypt

  • faulty of medicine, Tanta Univeristy

    RECRUITING

    Tanta, Gharbia Governorate, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.